CF
DYN icon

Corebridge Financial’s Dyne Therapeutics DYN Stock Holding History

Corebridge Financial’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,946
Closed -$428K – 824
2025
Q1 		$428K Sell
40,946
-50
-0.1% -$715 ﹤0.01% 1681
2024
Q4 		$966K Sell
40,996
-2,151
-5% -$63.6K 0.01% 1340
2024
Q3 		$1.55M Sell
43,147
-267
-0.6% -$10.6K 0.01% 1156
2024
Q2 		$1.53M Buy
+43,414
New +$1.26M 0.01% 1113

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's DYN Position: Q2 2025 in Review

Corebridge Financial sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 40,946 shares — an estimated $428K sold.

Corebridge Financial first reported a position in DYN in Q2 2024 and held it in 4 quarters. The position peaked at $1.55M in Q3 2024. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Corebridge Financial reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 40,946 Dyne Therapeutics shares in Q2 2025, an estimated $428K.
  • Corebridge Financial first reported a position in Dyne Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Dyne Therapeutics position peaked at $1.55M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.